Congressmen rally against AMP rule
Executive Summary
Ten legislators participate in a National Community Pharmacists Association rally to draw attention to looming Medicaid pharmacy reimbursement cuts. Numerous congressmen have expressed concern about CMS' proposed average manufacturer price rule through letters to CMS and HHS, but the agencies have not responded (1"The Pink Sheet" Feb. 26, 2007, p. 19). "Only someone whose intent was to enrich one party and take advantage of another could come up with such a goofy scheme. ... It is too bad that we have to take legislative action," said Marion Berry, D-Ark., author of one of the letters. CMS' final AMP rule is due by July 1...
You may also be interested in...
Legislators AMPlify Pharmacy Medicaid Concerns
Pharmacy groups worried about the impact of Medicaid's proposed changes in prescription drug payment have found friends in Congress who contend that the changes go beyond congressional intent
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.